News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

29

Mar

18
KemPharm Reports Fourth Quarter and Year End 2017 Results
- Press

21

Mar

18
KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results
- Press

20

Mar

18
Positive Topline Results from KP415 PK Study in Children/Adolescents With ADHD
- Featured
- Press

07

Mar

18
KemPharm to Present at Upcoming Investor Conferences
- Press

23

Feb

18
KemPharm Announces FDA Approval of Apadaz™
- Featured
- Press

31

Jan

18
MoneyShow Orlando Conference
- Press

12

Jan

18
KP415 – APSARD 2018
- Posters

28

Oct

17
KP201/IR – Pain Medicine
- Publications

25

Aug

17
Apadaz® – Pain Medicine
- Publications

03

Aug

17
Apadaz® – Drug Safety
- Publications

19

Mar

17
KP201/IR – AAPM 2017
- Posters

15

Mar

17
KP511 – AAPM 2017
- Posters